We provided evidence that colon cancer patients harboring the BRAF(V600E) oncogenic mutation were lack a significant response to PLX4720, but BRAF and EGFR inhibition can be synergistic when combined, suggesting more combining targeted agents can be used in clinical trials. Here, EGFR is linked to malignant colon neoplasm.